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We read with great interest the recently pub-lished article entitled ‘Evaluation of sub-
clinical atherosclerosis in Egyptian psoriatic
patients’ by Elsheikh et al. [1]. In that very well-
presented article, the authors evaluated the pres-
ence of subclinical atherosclerosis in patients with
psoriasis by using carotid ultrasonography. They
concluded that the average common carotid-in-
tima media thickness (cIMT), internal diameter
(ID) and arterial wall mass index (AWMI) can
identify patients with subclinical atherosclerosis
who need special follow-up to reduce cardiovas-
cular morbidity and mortality. Given the prognos-
tic value of this test, patients with psoriasis might
be at risk for future cardiovascular events and car-
diovascular mortality.
Psoriasis as a chronic inflammatory proliferative
skin disorder is diagnosed by a variety ofimmunologic and inflammatory changes and
may similarly predispose for those disorders [2].
It is speculated that increased inflammation of
psoriasis contributes to atherogenesis, the devel-
opment of coronary artery disease. We previously
investigated the relation between psoriasis and
atherosclerotic pattern as arterial stiffness param-
eters (ASPs). We concluded that psoriasis patients
had higher ASPs compared with control subjects
[3]. Therefore, because ASPs were higher in psori-
asis patients, they may have shown subclinical
atherosclerosis in these patients. Secondly, psoria-
sis is associated with an increased risk of cardio-
vascular disease. Endothelial dysfunction is
widely regarded as being the initial process in
the development of atherosclerosis. Human
endothelial cell-specific molecule-1 (endocan) is
a novel human endothelial cell-specific molecule.
Serum endocan levels were significantly different
between the two groups. Psoriasis vulgaris isNC-ND
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sis. cIMT levels are markers of systemic inflamma-
tion and are widely used as a prominent marker
for cardiovascular diseases. Patients with psoriasis
had a significantly greater cIMT compared with
control subjects [4]. In patients with psoriasis,
serum endocan levels correlated with the psoriasis
area and severity index, high-sensitivity C-reac-
tive protein (hsCRP) and cIMT [2]. Circulating
endocan may represent a new marker that corre-
lates with cardiovascular risk as well as the sever-
ity of disease in patients with psoriasis vulgaris.
Endocan may be a surrogate endothelial dysfunc-
tion marker and may have a functional role in
endothelium-dependent pathological disorders
[2]. Psoriatic disease patients with inflammatory
arthritis were closely associated with higher risk
of metabolic syndrome. Psoriatic arthritis patients
have significantly higher cIMT values compared
to patients with psoriasis alone. It would be useful,
and results might be different, if the authors had
described these factors.
Different conditions such as diabetes mellitus,
hypertension, asthma, various cancers, and
inflammatory diseases such as systemic lupus
erythematosus, rheumatoid arthritis, alcohol
consumption, smoking, hypercholesterolemia,
hypothyroidism, obstructive sleep apnea, nonal-
coholic fatty liver disease, heart failure, cere-
brovascular disease, and peripheral arterial
disease that may be built on common pro-inflam-
matory conditions are functionally linked to the
same etiologic factor [5]. For these reasons, had
the authors mentioned these factors, the results
of their study may have been different.In conclusion, markers of inflammation are use-
ful for the prediction of subclinical atherosclerosis.
However, while cIMT easily detects inflammation
and is readily available for clinical purposes,
serum cIMT levels are used as non-invasive mark-
ers in the assessment of subclinical atherosclerosis
in the study by Elsheikh et al and these can be
affected by many factors. cIMT itself with no other
inflammation markers may not provide enough
information to clinicians about atherosclerosis in
psoriasis patients. We think that it should be used
together with other inflammatory markers. We
believe such findings will prompt further studies
on cIMT and the atherosclerotic pattern in psoria-
sis patients.
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